You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,488,654


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,488,654
Title:Methods for predicting response of triple-negative breast cancer to therapy
Abstract: The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
Inventor(s): Liu; Xinjun (San Diego, CA), Kim; Phillip (Irvine, CA), Kirkland; Richard (San Diego, CA), Lee; Tani (San Diego, CA), Ybarrondo; Belen (San Diego, CA), Singh; Sharat (Rancho Sante Fe, CA)
Assignee: DIATECH HOLDINGS, INC. (Franklin, TN)
Application Number:13/545,947
Patent Claims:1. A method for determining whether a human subject with a triple-negative breast cancer will respond to therapy with a combination of bevacizumab (Avastin.RTM.), carboplatin, and paclitaxel, the method comprising: (a) obtaining a breast tumor sample from the human subject; (b) determining an expression profile in said sample of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein using a proximity immunoassay by contacting the sample with (1) capture antibodies that bind to each of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein, and (2) detection antibodies comprising first and second activation state-independent antibodies that bind to each of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein, wherein the capture antibodies are attached to a solid support, wherein the first activation state-independent antibodies are labeled with glucose oxidase, wherein the second activation state-independent antibodies are labeled with horseradish peroxidase, and wherein the binding of the first and second activation state-independent antibodies in proximity to each other generates a detectable signal; (c) comparing said expression profile to a reference expression profile comprising a median expression level of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein in a human population of triple-negative breast tumors; and (d) determining whether the human subject with a triple-negative breast cancer will respond to therapy with a combination of bevacizumab (Avastin.RTM.), carboplatin, and paclitaxel based on altered expression of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein in the sample relative to the reference expression profile, wherein decreased expression of VEGFR2 protein relative to the median expression level of VEGFR2 protein, decreased expression of c-KIT protein relative to the median expression level of c-KIT protein, increased expression of HER1 protein relative to the median expression level of HER1 protein, and decreased expression of IGF-1R protein relative to the median expression level of IGF-1R protein is indicative of response to therapy with the combination of bevacizumab (Avastin.RTM.), carboplatin, and paclitaxel.

2. The method of claim 1, wherein the triple-negative breast cancer is triple-negative metastatic breast cancer.

3. The method of claim 1, wherein the paclitaxel is a nanoparticle albumin-bound (nab) paclitaxel.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.